Description

This issue of Vital Signs, released on November 23, 2009, provides a strategic overview of trends in pharmacogenomic testing and drug development. Additionally, a company spotlight is provided for Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative new therapies that treat and prevent infectious diseases and other disorders. Reimbursement and regulatory news from the FDA is also provided for the week of November 9, 2009.